Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by themagicboxon Mar 31, 2022 12:53pm
218 Views
Post# 34563635

Otena still in the game

Otena still in the gameOn a more productive note, I found a very interesting drug for rheumatoid arthritis called baricitinib. Its getting traction in the news because of Jada smiths alopacia indicdent. https://en.wikipedia.org/wiki/Baricitinib

Anyway, this Eli lily drug got rejected by the FDA in April 2017 for "concerns about dosing and safety" but was approved a year later. 

And in 2020 the FDA granted it "breakthrough therapy" designation to baricitinib for the treatment of alopecia.

When I reviewed the concenrs for dosing and safety, it was a some serious stuff. Hardly comparable to the Otenas elevated ALTs. Food for thought. 

I am looking forward to seeing what happens with Otena in the next 2 years.
<< Previous
Bullboard Posts
Next >>